Author

Simon Dalla Torre di Sanguinetto

Observed names: S. Dalla-Torre, Simon A Dalla Torre di Sanguinetto, Simon Andreas Dalla Torre di Sanguinetto, Simon Dalla Torre Di Sanguinetto, Simon Dalla Torre di Sanguinetto

Institution: Swissmedic

Observed institutions: Swissmedic, University of Basel, Friedrich Miescher Institute

ORCID: 0000-0002-0808-4638

Observed ORCID: 0000-0002-0808-4638

OpenAlex ID: A5015818525

Transcriptional mechanisms controlling motor neuron diversity and connectivity

2008 · Simon A Dalla Torre di Sanguinetto, Jeremy S Dasen, et al. · Current Opinion in Neurobiology · 110

A decade comparison of regulatory decision patterns for oncology products to all other non‐oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration

2023 · Ulrich‐P. Rohr, Mario Iovino, et al. · Clinical and Translational Science · 19

PDF

Regulatory Review Duration and Differences in Submission Times of Drugs in the United States and Europe, 2011 to 2020

2023 · Kerstin N. Vokinger, Miquel Serra-Burriel, et al. · Annals of Internal Medicine · 18

A Comparative Review of Marketing Authorization Decisions in Switzerland, the EU, and the USA

2018 · Simon Dalla Torre Di Sanguinetto, Esa Heinonen, et al. · Therapeutic Innovation & Regulatory Science · 9

An Evaluation of the Swissmedic Regulatory Framework for New Active Substances

2023 · Magda Bujar, Simon Andreas Dalla Torre di Sanguinetto, et al. · Therapeutic Innovation & Regulatory Science · 3

PDF

Efficacy and Safety Evidence Supporting Cancer Drug Approvals in Switzerland (2001–2020): A Meta-Analysis of Pivotal Randomised Controlled Trials

2026 · Parisa Rahimzadeh, Qiyu Li, et al. · The Lancet Regional Health - Europe · 1

PDF

Trends in pivotal clinical trial design and biomarker use: a retrospective analysis of oncology drug approval in Switzerland from 2001 to 2020

2025 · Parisa Rahimzadeh, Qiyu Li, et al. · BMJ Connections Oncology · 1

PDF

1349P A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products between Swissmedic, EMA and FDA

2022 · U-P. Rohr, M. Iovino, et al. · Annals of Oncology

PDF

Works count: 8

Citation count: 161

H-index: 4

I10-index: 3